$2.31 Billion is the total value of Vivo Capital, LLC's 59 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
IGMS | Exit | IGM Biosciences Inc | $0 | – | -20,000 | -100.0% | -0.05% | – |
VYNE | Exit | VYNE Therapeutics Inc | $0 | – | -234,877 | -100.0% | -0.06% | – |
CNST | Exit | Constellation Pharmaceutical | $0 | – | -140,298 | -100.0% | -0.12% | – |
ATRC | Exit | Atricure Inc | $0 | – | -64,573 | -100.0% | -0.15% | – |
KALA | Exit | Kala Pharmaceuticals, Inc. | $0 | – | -786,883 | -100.0% | -0.19% | – |
CGEM | Exit | Cullinan Management Inc | $0 | – | -250,000 | -100.0% | -0.37% | – |
AKRO | Exit | Akero Therapeutics Inc | $0 | – | -673,280 | -100.0% | -0.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
CODEXIS INC | 29 | Q3 2023 | 8.0% |
ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
AMYRIS INC | 23 | Q3 2023 | 8.8% |
EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-22 |
13F-HR | 2024-02-07 |
13F-HR | 2023-11-08 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.